23873-27-0

Basic information

• Product Name: 4,4'-(ethylenediimino)bis[4-oxobutyric] acid
• Synonyms: 4,4'-(ethylenediimino)bis[4-oxobutyric] acid;4,4'-(Ethylenebisimino)bis(4-oxobutanoic acid);N,N'-Ethylenebissuccinamidic acid;N,N'-ETHYLENEBIS(SUCCINAMIC ACID)
• CAS NO: 23873-27-0
• Molecular Formula: C₁₀H₁₆N₂O₆
• Molecular Weight: 260.24384
• EINECS: 245-920-5
• Mol File: 23873-27-0.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 718.2°Cat760mmHg
• Flash Point: 388.1°C
• Appearance: /
• Density: 1.336g/cm³
• CAS DataBase Reference: 4,4'-(ethylenediimino)bis[4-oxobutyric] acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4'-(ethylenediimino)bis[4-oxobutyric] acid(23873-27-0)
• EPA Substance Registry System: 4,4'-(ethylenediimino)bis[4-oxobutyric] acid(23873-27-0)

Safety Data

• Hazardous Substances Data: 23873-27-0(Hazardous Substances Data)

Usage

General Description

4,4'-(ethylenediimino)bis[4-oxobutyric] acid, also known as ethylenediamine tetraacetic acid (EDTA), is a chemical compound commonly used as a chelating agent in various industrial and household products. It is a polydentate ligand, meaning it can form several bonds with a metal ion, making it useful in the removal of metal ions from solutions. EDTA is also used as a preservative in foods, as a stabilizer in cosmetics and pharmaceuticals, and as a water softening agent. Additionally, it is employed in the medical field for treating heavy metal poisoning and as an anticoagulant for blood samples. However, there are environmental concerns about the persistence of EDTA in the environment and its potential effects on ecosystems.

Upstream product

• 108-30-5 succinic acid anhydride 
• 107-15-3 ethylenediamine 

Relevant articles and documents

Efficient one-pot synthesis of doxorubicin conjugates through its amino group to melanotransferrin p97

The amino group of doxorubicin 1 is reacted with bis-NHS-ester linkers 6, or anhydrides 13 to offer in high yield modified doxorubicins 7-12 and 14-16, respectively. Compounds 7-12 are mono-NHS-esters, and can be directly coupled with melanotransferrin (p97), a useful vector with the ability to cross the blood-brain barrier, to yield the expected doxorubicin-p97 conjugates. Upon activating the carboxylic group with BTTU, compound 14-16 could be used in the same reaction. Structurally, the amino group of doxorubicin is covalently bonded to the amino groups of p97. The conjugates are potential candidates for treatment of brain tumors.

Bivalent HIV-1 fusion inhibitors based on peptidomimetics

Membrane fusion is a valid target for inhibition of HIV-1 replication. A 34-mer fragment peptide (C34), which is contained in the HIV-1 envelope protein gp41, has significant anti-HIV activity. Previously, a dimeric derivative of C34 linked by a disulfide bridge at its C-terminus was found to have more potent anti-HIV activity than the C34 peptide monomer. To date, several peptidomimetic small inhibitors have been reported, but most have lower potency than peptide derivatives related to C34. In the present study we applied this dimerization concept to these peptidomimetic small inhibitors and designed several bivalent peptidomimetic HIV-1 fusion inhibitors. The importance of the length of linkers crosslinking two peptidomimetic compounds was demonstrated and several potent bivalent inhibitors containing tethered peptidomimetics were produced.

Protein crosslinkers, crosslinking methods and applications thereof

Some aspects of this disclosure relate to a method for crosslinking a biological fluid comprising combining a biological fluid with a crosslinker to covalently crosslink proteins endogenous to the biological fluid to form a crosslinked gel. Examples of a biological fluid are blood, plasma, or serum.